Mentice

Mentice CapEx/D&A

The CapEx to Depreciation Ratio of Mentice (MNTC.ST) as of Nov 19, 2026 is 0.54. In the previous year, CapEx to Depreciation Ratio was 0.25 — a change of 113.11% (higher).

CapEx/D&A

0.54

YoY

113.11%

Last updated:

CapEx to Depreciation Ratio of Mentice is 2024 0.54 . CapEx to Depreciation Ratio of Mentice was 2023 0.25 . It decreases by 113.11% higher compared to the previous year.

The Mentice CapEx/D&A history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/D&A
Date
CapEx/D&A
Jan 1, 2017
2.67 SEK
Jan 1, 2018
2.66 SEK
Jan 1, 2019
0.34 SEK
Jan 1, 2020
1.79 SEK
Jan 1, 2021
1.17 SEK
Jan 1, 2022
0.57 SEK
Jan 1, 2023
0.25 SEK
Jan 1, 2024
0.54 SEK
The Mentice CapEx/D&A history
YEARCapEx/D&AYoY
0.54+113.11%
0.25-55.69%
0.57-51.27%
1.17-34.81%
1.79+421.67%
0.34-87.10%
2.66-0.35%
2.67—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mentice Stock analysis

What does Mentice do? Mentice AB provides software and hardware simulation solutions for endovascular therapies, targeting healthcare professionals and the medical device industry. The company's solutions are scientifically validated and designed to help users acquire, retain, and enhance procedural skills in neurovascular, cardiovascular, and peripheral interventions. Mentice AB generates revenue through the sale of its simulation products and related services, with key buyers including healthcare providers and medical device manufacturers. The company operates globally, serving clients across multiple healthcare segments that require advanced training tools for minimally invasive procedures. Mentice AB's business model focuses on delivering scientifically validated simulation tools that address skill development needs in complex medical procedures. The firm's product offerings cater to both healthcare institutions seeking to train staff and medical device companies requiring validation tools for their products. By specializing in endovascular therapy simulations, Mentice AB serves a niche market with high demand for precise procedural training solutions. The company's global presence allows it to reach clients in various regions seeking advanced medical simulation technology. The company's revenue streams come from the sale of simulation software and hardware systems alongside ongoing service contracts. Healthcare providers purchase these solutions to improve staff competency in endovascular procedures, while medical device manufacturers use them to validate device performance in simulated environments. Mentice AB's solutions are specifically developed for the medical device industry and healthcare providers, creating a dual revenue stream from both sectors. The firm's focus on scientifically validated tools ensures strong market positioning within specialized medical training segments. Mentice is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mentice stock

CapEx to Depreciation Ratio of Mentice is 0.54 in 2024.

CapEx to Depreciation Ratio of Mentice changed from 0.25 to 0.54, representing a 113.11% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Depreciation Ratio Mentice since 2006 – with annual values, charts, and detailed analysis.

The CapEx/D&A ratio compares investment spending to asset depreciation. Ratios above 1.0x indicate the company is growing its asset base, below 1.0x suggests underinvestment.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Depreciation Ratio's Mentice with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Depreciation Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Depreciation Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Mentice

All Key Metrics — Mentice